Promising Clinical Trial Results Drive Buy Rating for Bicara Therapeutics
In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report), ...
ETF Daily News9 天
Bicara Therapeutics Initiates Corporate Presentation on Promising Corporate Strategy
Bicara Therapeutics Inc., a company dedicated to innovative therapies, made public its intent to furnish a corporate presentation on January 13, 2025. The presentation, as detailed in its Form 8-K ...
Bicara's Ficerafusp Alfa Plus Pembrolizumab Combo Shows Positive Data In Cancer Study ...
(RTTNews) - Bicara Therapeutics Inc. (BCAX), Monday announced the results from the Phase 1/1b dose expansion cohort, evaluating the combination of ficerafusp alfa with pembrolizumab in patients with ...